There is provided a stable enzyme composition comprising glutathione peroxidase and at least one stabilizer compound selected from the group consisting of pentoses, hexoses, penthahydric sugar alcohols, hexahydric sugar alcohols and disaccharides.
|
1. A stable enzyme composition in freeze-dried form comprising glutathione peroxidase and at least one stabilizer compound selected from the group consisting of pentoses, hexoses, pentahydric sugar alcohols, hexahydric sugar alcohols and disaccharides.
2. The composition as claimed in
3. The composition as claimed in
4. The composition as claimed in
5. The composition as claimed in
6. The composition as claimed in
7. The composition as claimed in any of the preceding claims, wherein the amount of the stabilizer compound is at least equal to the protein weight of glutathione peroxidase.
8. The composition as claimed in
|
The present invention relates to a stable composition of glutathione peroxidase (Glutathione: hydrogen peroxide oxidoreduclase, EC 1. 11. 1.9).
Glutathione peroxidase was derived from bovine erythrocytes by Mills in 1957 [J. Biol. Chem., 229, 189 (1957)], and is known as a metalloenzyme containing selenium. This enzyme catalyzes the reaction shown by the following formula (L), and also, even when hydrogen peroxide in the formula (1) is replaced with t-butyl hydroperoxide, cumene hydroperoxide, lauryl hydroperoxide or progesterone-17-α-hydroperoxide, it will easily decompose these peroxides in the presence of reduction type glutathione.
2GSH+H2 O2 →GSSG+2H2 O (1)
GSH: Reduction type glutathione
GSSG: Oxidation type glutathione
Said enzyme is obtained from the organs such as erythrocytes, liver, crystalline lens, etc. of various animals (man, cow, sheep, rat, pig, etc.), and the method for its purification is already well known. For example, there are some methods reported by S. H. Oh et al. [Biochemistry, 13, 1825 (1974)], Nakamura et al. [Biochem. Biophys. Acta, 358, 251 (1974)], Yagi et al. [The Proceedings on the 52nd Meeting of Biochemical Society of Japan, 723 (1979)] and the like. Relating to a storage and stabilization method for the purified enzyme, methods such as storage in phosphate buffers (pH, 7.0), storage in ethanol solution, freeze storage in the presence of a reducing agent (e.g. glutathione, dithiothreitol) and the like are known. These known stabilization methods are limited to the stabilization of said enzyme for up to three months. And the glutathione peroxidase preserved by methods other than freeze storage in the presence of a reducing agent retains its activity at only 60 to 80% (reference is an activity value just before storage) after one month cold storage. The freeze storage in the presence of a reducing agent shows an activity retention of about 90% after three months storage, but such method has various disadvantages such that freezing is necessary for storage, and transportation of the frozen preparation is not easy.
We have conducted research to find a new method which is superior in stability to the known methods and requires no freeze storage, and as a result, have found that, when a sugar or sugar alcohol is added to said enzyme as a stabilizer, an enzyme composition much superior in stability as compared with the prior-art stabilized compositions can be obtained.
According to the present invention, there is provided a stable enzyme composition comprising glutathione peroxidase and one or more compounds selected from the group consisting of pentoses, hexoses, pentahydric sugar alcohols, hexahydric sugar alcohols and disaccharides.
In the present invention, glutathione peroxidase, when added with the foregoing stabilizer, becomes extremely superior in stability and superior in storage stability as compared with the use of conventional stabilizers.
Glutathione peroxidase used in the present invention may be from any source and not limited to those which are obtained from the organs such as erythrocytes, liver, crystalline lens, etc. of various animals (e.g. man, cow, sheep, rat, pig, etc.).
The pentoses used in the present invention include for example D-, L-arabinose, D-, L-xylose, D-, L-lyxose, D-ribose, D-, L-xylulose, D-, L-ligrose and the like.
The hexoses include for example D-, L-galactose, D-glucose, D-mannose, D-sorbose, D-fructose and the like.
The pentahydric sugar alcohols used in the present invention include for example D-arabitol, xylitol and the like.
The hexahydric sugar alcohols include for example galactitol, D-sorbitol, D-mannitol and the like.
Further, the disaccharides include for example xylobiose, maltose, isomaltose, laminaribiose, cellobiose, gentiobiose, lactose, sucrose and the like.
The amount of stabilizer used in the present invention is equal to or more than the protein weight of glutathione peroxidase, preferably 1 to 10 times the protein weight.
As a method for mixing the enzyme and the stabilizer, there may be employed any proper method, for example a method in which a buffer solution containing dissolved enzyme is mixed with a solution containing the foregoing stabilizer dissolved; a method in which the enzyme and the stabilizer are mixed in a buffer solution; and a method in which the enzyme is mixed with a solution containing dissolved stabilizer. Solutions containing the enzyme and stabilizer may be stored as they are or in freeze drying. Freeze drying may be carried out as usual.
The stabilized glutathione peroxidase composition obtained in the present invention is superior in stability as compared with those in the known methods, showing an activity retention of not less than about 80% even after six months storage. Further, there is no need for freezing during storage, and the activity retention is not affected by temperature, if the enzyme is stored at a temperature not higher than 20°C
In this invention, measurement of enzyme activity was conducted as follows: Using 2 ml of a 50 mM phosphate buffer solution (pH 7.0) containing 2 mM EDTA, 1 mM glutathione, 1 mM sodium azide, 0.16 mM NADPH, 0.4 mM hydrogen peroxide, 0.14 unit glutathione reductase and 0.01 unit glutathione peroxidase, the absorbance at 340 nm of the solution was recorded at 25°C for 3 minutes on a spectrophotometer, and a change in absorbance per minute was obtained from the linear portion. The blank value was obtained by using water in place of the enzyme solution.
As for the unit of glutathione peroxidase, the amount of the enzyme necessary to decompose 0.5 μmole of NADPH in one minute under the foregoing reaction condition was taken as one unit.
The invention will be further explained in the following Examples which are given for illustration only and not for limiting the scope of the invention.
From bovine blood, glutathione peroxidase was purified according to the method of Yagi et al. [The gist of the lectures at the 52nd Meeting of Biochemical Society of Japan, 723 (1979)]. Thus, 10 liters of the bovine blood (sodium citrate was added as anti-coagulant) was centrifuged to remove the plasma fraction, and after washing with a physiological saline water, about 5 liters of erythrocyte was obtained by centrifugation. The erythrocyte obtained (5 liters) was hemolyzed with addition of 2.5 liters of distilled water, and then 2.625 liters of carbon tetrachloride and 5.85 liters of ethanol were added with stirring to modify and deposit hemoglobin. Thereafter, 7.5 liters of distilled water was added, and about 15 liters of the supernatant liquor was separated by centrifugation. From the supernatant liquor obtained, glutathione peroxidase could be separated in a yield of about 20% by applying column chromatography with DEAE Sephadex A-50, Sephacryl S-200, Activated thiol 4B and Sephadex G-150.
A 50 mM phosphate buffer solution (pH 7.0) of the glutathione peroxidase obtained was concentrated to a protein concentration of 10 mg/ml using a ultrafilter (Toyo Kagaku Sangyo K.K.). To the phosphate buffer solution containing said enzyme was added each of the substances under the condition shown in Table 1, followed by freeze drying. The activity retention after storage for the required period of time is shown in Table 1.
TABLE 1 |
______________________________________ |
Activity retention (%)*1 |
Addition 0 1 3 6 |
Stabilizer ratio*2 |
day month months |
months |
______________________________________ |
Pre- Arabinose 1 92 92 90 87 |
sent Glucose 1 94 92 89 84 |
inven- |
Xylitol 1 95 92 90 85 |
tion Sorbitol 1 95 92 90 88 |
Sucrose 1 97 95 95 93 |
Com- Erythrose 1 69 65 60 52 |
para- Heptulose 1 63 60 55 48 |
tive Erythritol 1 60 51 48 40 |
exam- Sedoheptitol |
1 65 58 52 39 |
ple Amylose 1 70 65 50 35 |
No addition |
-- 50 30 27 20 |
______________________________________ |
*1 Storage was carried out at 4°C The activity retention wa |
calculated with the activity value before freeze drying as 100%. |
*2 Weight of added substance/weight of said enzyme protein. |
Glutathione peroxidase obtained in the same manner as in Example 1 was similarly concentrated to a protein concentration of 10 mg/ml using ultrafilter, and the stabilizer shown in Table 2 was added at various addition ratios, followed by freeze drying. The results are shown in Table 2.
TABLE 2 |
______________________________________ |
Addition Activity retention (%) |
Stabilizer |
ratio 3 months 6 months |
______________________________________ |
Arabinose 4 92 87 |
1 91 87 |
0.5 79 65 |
Glucose 4 90 85 |
1 90 84 |
0.5 77 63 |
Xylitol 4 91 86 |
1 89 85 |
0.5 78 66 |
Sorbitol 4 91 88 |
1 91 87 |
0.5 75 61 |
Sucrose 4 95 94 |
1 96 93 |
0.5 79 68 |
______________________________________ |
Storage was carried out at 4°C |
Glutathione peroxidase obtained in the same manner as in Example 1 was similarly concentrated (to a protein concentration of 10 mg/ml) using a ultrafilter, and the stabilizer was added thereto in an amount equivalent (addition ratio, 1) to the protein weight. The mixture was freeze-dried and stored at a temperature shown in Table 3.
TABLE 3 |
______________________________________ |
Storage |
temperature Activity retention (%) |
Stabilizer |
(°C.) 3 months 6 months |
______________________________________ |
Arabinose 30 71 61 |
20 90 84 |
4 91 86 |
Glucose 30 69 59 |
20 87 83 |
4 90 85 |
Xylitol 30 73 62 |
20 89 83 |
4 90 85 |
Sorbitol 30 72 60 |
20 90 86 |
4 91 88 |
Sucrose 30 71 60 |
20 95 92 |
4 96 94 |
______________________________________ |
Glutathione peroxidase obtained in the same manner as in Example 1 was similarly concentrated using a ultrafilter to obtain a 25 mM phosphate buffer solution (pH 7.0) having a protein concentration of 10 mg/ml. To this phosphate buffer solution was added each of the stabilizers described below in an amount of 1/250 per weight of enzyme protein. The enzyme activity retention of the resulting solution is shown in Table 4. Also, an enzyme activity retention when ethanol was added to this phosphate buffer to be 24% of ethanol solution is shown together.
TABLE 4 |
______________________________________ |
Activity retention (%) |
Stabilizer 0 day 1 month 3 months |
6 months |
______________________________________ |
None 100 65 40 35 |
Glutathione 100 70 60 49 |
Dithiothreitol |
100 98 80 59 |
Glutathione + |
100 98 90 60 |
dithiothreitol |
24% Ethanol 100 98 80 40 |
solution |
______________________________________ |
Shimizu, Hiroshi, Ogawa, Satoshi, Kobayashi, Setsuo, Beppu, Kazuo, Kotani, Ryotaro
Patent | Priority | Assignee | Title |
10064404, | Jun 10 2014 | BIOMATRICA, INC | Stabilization of thrombocytes at ambient temperatures |
10568317, | Dec 08 2015 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
10772319, | Jun 10 2014 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
11116205, | Dec 08 2015 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
11672247, | Jun 10 2014 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
4684615, | Jun 06 1983 | Chiron Diagnostics Corporation | Stabilized isoenzyme control products |
4699882, | Jun 25 1985 | STABRA AG, A CO OF SWITZERLAND | Stable glucose isomerase concentrate and a process for the preparation thereof |
4810633, | Jun 04 1984 | MILES INC | Enzymatic ethanol test |
4992372, | Feb 02 1989 | ENZYMOL INTERNATIONAL, INC | Method for removing impurities from peroxidase solutions |
5200462, | Jan 25 1991 | CLINICAL DIAGNOSTIC SYSTEMS INC | Succinimide containing polymers and lattices prepared from same |
5308749, | Jan 25 1991 | CLINICAL DIAGNOSTIC SYSTEMS INC | Method of preparing biologically active reagents from succinimide-containing polymers, analytical element and methods of use |
5449663, | Jun 11 1993 | Antineoplastic compositions | |
5556771, | Feb 10 1995 | Hologic, Inc; Biolucent, LLC; Cytyc Corporation; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC ; Third Wave Technologies, INC; Gen-Probe Incorporated | Stabilized compositions of reverse transcriptase and RNA polymerase for nucleic acid amplification |
5614387, | Feb 10 1995 | Hologic, Inc; Biolucent, LLC; Cytyc Corporation; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC ; Third Wave Technologies, INC; Gen-Probe Incorporated | Method of making stabilized enzyme compositions for nucleic acid amplification |
5834254, | Feb 10 1995 | Hologic, Inc; Biolucent, LLC; Cytyc Corporation; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC ; Third Wave Technologies, INC; Gen-Probe Incorporated | Stabilized enzyme compositions for nucleic acid amplification |
5876992, | Jul 03 1996 | Molecular Biology Resources, Inc. | Method and formulation for stabilization of enzymes |
6294365, | Jul 03 1996 | MOLECULAR BIOLOGY RESOURCES, INC , A WISCONSIN CORPORATION | Method and formulation for stabilization of enzymes |
6509146, | May 29 1996 | QUADRANT DRUG DELIVERY LIMITED, FORMERLY ELAN DRUG DELIVERY LIMITED | Scalable long-term shelf preservation of sensitive biological solutions and suspensions |
6667167, | Mar 12 1997 | NOVOZYMES A S | Storage-stable liquid formulation comprising a laccase |
6835811, | Mar 13 2001 | Kromar Medical Corporation | Extended storage of reduced glutathione solutions |
7319032, | Apr 22 2004 | MedTox | Non-sugar sweeteners for use in test devices |
7449546, | Mar 13 2001 | Kromar Medical Corporation | Method for extending storage of glutathione solutions and methods for treating Parkinson's disease with said stored glutathione solutions |
8519125, | May 11 2009 | MXCGLOBAL INC | Compositions and methods for biological sample storage |
8900856, | Apr 08 2004 | BIOMATRICA, INC | Integration of sample storage and sample management for life science |
9078426, | Apr 08 2004 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
9314519, | Aug 21 2012 | INTERVET INC | Liquid stable virus vaccines |
9376709, | Jul 26 2010 | BIOMATRICA, INC | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
9393298, | Mar 15 2013 | INTERVET INC | Liquid stable bovine virus vaccines |
9480739, | Mar 15 2013 | INTERVET INC | Bovine virus vaccines that are liquid stable |
9526780, | Aug 21 2012 | Intervet Inc. | Liquid stable virus vaccines |
9603924, | Mar 15 2013 | INTERVET INC | Bovine virus vaccines that are liquid stable |
9725703, | Dec 20 2012 | MXCGLOBAL INC | Formulations and methods for stabilizing PCR reagents |
9827305, | Feb 17 2014 | INTERVET INC | Poultry virus vaccines that are liquid stable |
9839613, | Sep 27 2013 | INTERVET INC | Dry formulations of vaccines that are room temperature stable |
9845489, | Jul 26 2010 | BIOMATRICA, INC | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
9855336, | Feb 19 2014 | INTERVET INC | Swine virus vaccines that are liquid stable |
9999217, | Jul 26 2010 | BIOMATRICA, INC | Compositions for stabilizing DNA, RNA, and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
Patent | Priority | Assignee | Title |
3133001, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Jun 15 1982 | KOBAYASHI, SETSUO | TOYO BOSEKI KABUSHIKI KAISHA, A CORP OF | ASSIGNMENT OF ASSIGNORS INTEREST | 004022 | /0524 | |
Jun 15 1982 | BEPPU, KAZUO | TOYO BOSEKI KABUSHIKI KAISHA, A CORP OF | ASSIGNMENT OF ASSIGNORS INTEREST | 004022 | /0524 | |
Jun 15 1982 | SHIMIZU, HIROSHI | TOYO BOSEKI KABUSHIKI KAISHA, A CORP OF | ASSIGNMENT OF ASSIGNORS INTEREST | 004022 | /0524 | |
Jun 15 1982 | OGAWA, SATOSHI | TOYO BOSEKI KABUSHIKI KAISHA, A CORP OF | ASSIGNMENT OF ASSIGNORS INTEREST | 004022 | /0524 | |
Jun 15 1982 | KOTANI, RYOTARO | TOYO BOSEKI KABUSHIKI KAISHA, A CORP OF | ASSIGNMENT OF ASSIGNORS INTEREST | 004022 | /0524 | |
Jul 01 1982 | Toyo Boseki Kabushiki Kaisha | (assignment on the face of the patent) | / |
Date | Maintenance Fee Events |
Nov 02 1987 | M170: Payment of Maintenance Fee, 4th Year, PL 96-517. |
Nov 26 1991 | M171: Payment of Maintenance Fee, 8th Year, PL 96-517. |
Dec 19 1991 | ASPN: Payor Number Assigned. |
Sep 29 1995 | M185: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
May 29 1987 | 4 years fee payment window open |
Nov 29 1987 | 6 months grace period start (w surcharge) |
May 29 1988 | patent expiry (for year 4) |
May 29 1990 | 2 years to revive unintentionally abandoned end. (for year 4) |
May 29 1991 | 8 years fee payment window open |
Nov 29 1991 | 6 months grace period start (w surcharge) |
May 29 1992 | patent expiry (for year 8) |
May 29 1994 | 2 years to revive unintentionally abandoned end. (for year 8) |
May 29 1995 | 12 years fee payment window open |
Nov 29 1995 | 6 months grace period start (w surcharge) |
May 29 1996 | patent expiry (for year 12) |
May 29 1998 | 2 years to revive unintentionally abandoned end. (for year 12) |